Active Commuting

Research summary

• Active commuting has one of the more consistent evidence bases linking an everyday habit to reduced mortality.
• A meta-analysis pooling 17 studies and 829,098 workers found active commuting reduced all-cause mortality by 9% and cardiovascular mortality by 15%, with cycling alone cutting all-cause mortality by 21% and cardiovascular mortality by 33% in a clear dose-response pattern -- higher levels of commuting activity produced larger reductions, while low levels of walking showed no measurable benefit.
• The UK Biobank cohort of over 263,000 adults corroborated this: cycle commuters had a hazard ratio of 0.59 for all-cause mortality and lower cardiovascular disease incidence than non-active commuters, with walking commuting also linked to lower cardiovascular disease risk though not all-cause mortality.
• A 25-year Danish cohort of 28,204 people found initiating cycling in mid-life was associated with a 22% lower mortality risk compared with those who never cycled, and a large England and Wales Census-linked cohort of nearly 400,000 workers found cycle commuters had 20% lower all-cause mortality and 24% lower cardiovascular mortality than car commuters.
• A UK Biobank biomarker analysis of over 208,000 adults found active commuting modes were associated with more favorable cardiovascular risk-marker profiles, evidence less vulnerable to the long-follow-up confounding that affects mortality studies.
• The main caveat, raised explicitly in a Chinese cohort of 76,176 adults, is that active commuting's benefits can be diminished by exposure to high ambient air pollution during the commute itself, and -- since no trial has randomly assigned people to commute actively -- all of this evidence remains observational, unable to fully separate the effect of the commute from the broader health and lifestyle differences of people who choose to walk or cycle to work.